- Savara press release ( NASDAQ: SVRA ): Q2 GAAP EPS of -$0.06 in-line.
- “Despite ongoing factors such as geographical COVID surges, geopolitical issues and supply chain constraints, IMPALA-2, the pivotal Phase 3 trial of our novel inhaled biologic, is currently on-track for a top line read-out by the end of 2Q 2024,” said Matt Pauls, Chair and CEO, Savara. “With a cash position of approximately $142M at the end of the second quarter of 2022, we are confident that we are funded through 2025, which is well beyond the expected IMPALA-2 read-out.”
For further details see:
Savara GAAP EPS of -$0.06 in-line